SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™
The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers
L'hôpital Avicenne, which serves approximately 500,000 patients annually across all areas of care, is a clinical, research, and teaching hospital, known for its expertise in oncology. L'hôpital Avicenne's clinical hematology department treats various hematological malignancies via 25 in-patient beds and outpatient care.
"As a research and teaching hospital, as well as a clinical center of excellence, it is our goal to offer all of our patients advanced and personalized care," said
Blood cancers are the fifth most common type of cancer in the world with roughly 1.3 million new cases reported annually.1 Advances in the study of blood cancers, as with many other cancers, depend on timely, cost-effective, and reliable sequencing strategies as well as high-quality and reproducible data. The SOPHiA DDM™ Platform uses next-generation sequencing (NGS) to target key variants from FFPE, blood, or bone marrow samples helping lead to better detection of variants associated with the disease. SOPHiA DDM™ is specifically designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect genomic variants associated with rare and challenging cases.
"At SOPHiA GENETICS we are passionate about accelerating and expanding the use of precision medicine. This is made possible by our AI-based technology that facilitates fast and accurate analysis of key data and helps draw relevant insights for researchers and clinicians to support them in making data-driven decisions," said Kevin Puylaert, Managing Director, EMEA,
The SOPHiA DDM™ Platform delivers results that are nearly 100 percent2 reproducible to provide consistent inter- and intra-run results, ensuring stable and trustworthy sequencing data. For more information on
About SOPHiA GENETICS
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
1
https://www.worldwidecancerresearch.org/news-opinion/2022/september/blood-cancer-everything-you-need-to-know/
2 99.3% observed
View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-lhopital-universitaire-avicenne-is-live-on-sophia-ddm-302208684.html
SOURCE